• Larimar Therapeutics Announces Oral Presentation at the Upcoming Gordon Research Conference on Mitochondria and Chloroplasts

    Source: Nasdaq GlobeNewswire / 28 Jun 2022 08:00:02   America/New_York

    BALA CYNWYD, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that biomarker studies that have identified genes that are differentially expressed between healthy individuals and those with Friedreich’s ataxia will be featured in an oral presentation at the upcoming Gordon Research Conference on Mitochondria and Chloroplasts during the session on “Organelle Biology Translated into Medicine and Agriculture.” The conference will take place July 17 – 22, 2022 at Mount Snow in West Dover, Vermont.

    Details on the presentation are shown below.

    Presentation Title:Identification of Differentially Expressed Genes in Friedreich’s Ataxia Patients
      
    Presenting Author:David Bettoun, Ph.D., Vice President of Discovery and Non-clinical R&D, Larimar Therapeutics
      
    Presentation Date:July 21, 2022
      
    Presentation Time:8:40 PM ET

    About Larimar Therapeutics
    Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

    Investor Contact:
    Joyce Allaire
    LifeSci Advisors
    jallaire@lifesciadvisors.com
    (212) 915-2569

    Company Contact:
    Michael Celano
    Chief Financial Officer
    mcelano@larimartx.com
    (484) 414-2715


    Primary Logo

Share on,